Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
U.S. Congress. House. To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. H.R. 679. 119th Cong., 1st sess., Introduced in House January 23, 2025. https://www.govinfo.gov/app/details/BILLS-119hr679ih.
Congress, House of Representatives (2025, January 23). To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. (H.R. 679 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr679ih.
United States, Congress, House of Representatives. To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr679ih. 119th Congress, H.R. 679, Introduced in House 23 Jan. 2025.
H.R.679 - 119th Congress (2025-2026): To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes., H.R.679, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119hr679ih.